NSCLC - Non Small Cell Lung Cancer Now Closed
Checkmate 816 / CA209-816 - Hosted By elie
Randomized, Open Label, Phase 3 Trial of Neoadjuvant Nivolumab and Ipilimumab Plus Chemotherapy Versus Platinum Doublet Chemotherapy Alone in Early Stage NSCLC
| Study Type | Treatment |
| Sponsor Name | BMS |
| Disease type | Non-Small Cell Lung Cancer |
| Disease Stage | IB – IIIA |
| Clinical Status | Neoadjuvant |
| Phase | III |
| Intervention / Treatment | Nivolumab and Ipilimumab + Chemotherapy versus Chemotherapy Alone |
| Research Site | McGill University Health Center |
| Investigator | Dre Jonathan Spicer |
| Coordinator | Nicolas Raby |
| Telephone number | |
| Fax number | – |
| Study start date | December 20, 2016 |
| Study end date | November 06, 2018 |
| Trial Status | Recruiting |
| Study Type | Treatment |
| Sponsor Name | |
| Tumor Site | NSCLC - Non Small Cell Lung Cancer |
| Disease Stage | Stage I, Stage II, Stage III |
| Clinical Status | Neo-Adjuvant, Operable |
| Phase | Phase I |
| Intervention / Treatment | |
| Research Site | Montreal, QC, McGill University Health Center, Montreal University Hospital Center |
| Investigator | |
| Coordinator | |
| Telephone Number | +1 (514) 934-4411 |
| Fax Number | |
| Study Start Date | |
| Study End Date | |
| Trial Status |
